English

BioStock: Alligator’s CEO: “We are on track to secure a partnership”

Report this content

Alligator Bioscience is undertaking a restructuring and planning a rights issue of approximately SEK 280 million. This move aims to concentrate efforts on its lead drug candidate, mitazalimab, with the goal of securing a partnership and advancing it to a phase III trial. BioStock spoke with CEO Søren Bregenholt to learn more.

Read the interview with Alligator Bioscience at biostock.se:

https://www.biostock.se/en/2024/12/alligators-ceo-we-are-on-track-to-secure-a-partnership/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

Subscribe

Documents & Links

Quick facts

BioStock: Alligator’s CEO: “We are on track to secure a partnership”
Tweet this